Abstract #2639

The USPIO GEH121333 as a dual R1 and R2 Contrast Agent for Imaging Response to Anti-angiogenic Therapy

Jana Cebulla¹, Eugene Kim¹, Dan E Meyer², Karina Langseth³, Tone F Bathen¹, Siver A Moestue¹, and Else Marie Huuse^1,4

¹Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, ²Diagnostics, Imaging and Biomedical Technologies, Niskayuna, NY, United States, ³GE Healthcare AS, Oslo, Norway, ⁴Department of Medical Imaging, St. Olavs University Hospital, Trondheim, Norway

Preclinical-phase iron oxide particles (GEH121333), with a high r₁/r₂ ratio compared to other iron oxide nanoparticles, were used for monitoring vascular response to bevacizumab treatment in ovarian cancer xenografts. Susceptibility contrast MRI using T₂ and T₂* mapping revealed a treatment induced decrease in blood volume and vessel density, but not in vessel size. Additionally, DCE-MRI using gadodiamide detected a decrease in perfusion and/or permeability. In combination, these two methods provide a comprehensive assessment of anti-angiogenic treatment effects.
Lastly, GEH121333 particles induced a strong signal increase in T₁w images, which shows promise for its use also as a positive contrast agent.

This abstract and the presentation materials are available to members only; a login is required.

Join Here